Acute Myeloid Leukemia (AML)
Aggressive bone marrow cancer requiring fast molecular diagnostics, risk-adapted induction treatment, and specialized medical intervention including the use of FLT3 inhibitors, venetoclax treatments, allogeneic transplantation, and CAR-T clinical trials for recurrent illness.
- AML subtypes & ELN risk groups
- FLT3 / IDH / NPM1 / TP53 testing & implications
- Targeted therapy, transplant & trial access
- Most Common In
- Adults (median age 68)
- Pediatric AML
- ~15-20% of childhood acute leukemias
- Key Test
- Bone Marrow Biopsy + NGS Panel
- Targeted Options
- FLT3 ยท IDH1/2 ยท BCL-2 ยท CD33
- Advanced Therapies
- Venetoclax ยท HMAs ยท Allo-SCT ยท CAR-T trials
What is Acute Myeloid Leukemia (AML)
Types and Subtypes
Classification of AML is trending towards molecular and cytogenetic categories under WHO and ICC systems. Classification is no longer only for identification purposes; rather, it influences treatment aggressiveness, transplantation, targeted therapies, and patient prognosis.
Symptoms and Signs
AML typically occurs within days or weeks. Symptoms arise due to the failure of bone marrow to make adequate amounts of normal red cells, neutrophils, and platelets, along with the effects of leukemia spreading to other organs.
Causes and Risk Factors
Most cases of AML occur without an identifiable cause. AML results from acquired genetic mutations in myeloid precursor cells. A minority of cases follow recognizable predisposing exposures or inherited syndromes.
Diagnosis and Investigations
Acute myeloid leukemia (AML) is an urgent hematological problem. Diagnostic evaluation not only confirms the diagnosis but also determines the type of AML and its therapeutic targets. Whether to include FLT3 and IDH inhibitors, as well as transplantation plans, should be decided based on the findings.
Risk Stratification (ELN 2022)
AML is not staged in the traditional anatomic sense. Instead, patients are classified into risk groups using the European LeukemiaNet (ELN) framework, which integrates cytogenetics and molecular findings. Risk group drives consolidation strategy, transplant planning, and clinical trial enrollment.
Standard Treatment
AML treatment is split between fit patients who can tolerate intensive chemotherapy and older or unfit patients for whom lower-intensity regimens are appropriate. APL has its own dedicated treatment pathway. Across all groups, molecular and cytogenetic findings shape regimen choice and the plan for transplant.
Advanced & Emerging Therapies
The landscape for the management of relapsed/refractory AML has changed dramatically with the advent of targeted agents, venetoclax-based regimens, and an array of cell-based treatments. Expert advice is crucial in this context, as the appropriate approach hinges critically on previous treatment, molecular features, and transplant suitability.
FLT3 Inhibition
Gilteritinib / Midostaurin / Quizartinib
Midostaurin is added to standard induction in FLT3-mutated newly diagnosed AML. Gilteritinib is the standard for relapsed/refractory FLT3-mutated AML. Quizartinib has been approved for FLT3-ITD AML in combination with chemotherapy. FLT3 inhibitor maintenance after transplant is increasingly used in FLT3-mutated disease.
IDH Inhibition
Ivosidenib (IDH1) / Enasidenib (IDH2)
Targeted differentiation agents for IDH1- or IDH2-mutated AML. Used in relapsed/refractory disease and increasingly in newly diagnosed older patients in combination with azacitidine. Differentiation syndrome is an important on-treatment consideration.
BCL-2 Inhibition
Venetoclax-Based Combinations
Venetoclax combined with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine is a widely used standard for older or unfit patients. Active investigation in fit patients, FLT3-mutated AML, and relapsed/refractory disease.
Antibody-Drug Conjugate
Gemtuzumab Ozogamicin (CD33-Targeted)
Anti-CD33 ADC. Added to standard induction in CD33-positive favorable- and intermediate-risk AML in selected patients. Improves outcomes when used appropriately.
Cellular Therapy
CAR-T and CAR-NK Therapy (CD33, CD123, CLL-1, FLT3)
Multiple AML-targeted CAR-T and CAR-NK programs are in clinical trials, targeting myeloid antigens such as CD33, CD123, CLL-1, and FLT3. Specialist centers in China and globally are advancing these programs. Access is currently primarily through clinical trials.
Bispecific T-cell Engagers
CD33 / CD123 Bispecific Antibodies
Bispecific antibodies engaging T cells against AML antigens are in active clinical development. Aim to provide an off-the-shelf alternative to CAR-T in relapsed/refractory disease.
Menin Inhibition
Revumenib and Other Menin Inhibitors
Targeted therapy for KMT2A-rearranged and NPM1-mutated AML. Promising activity in relapsed/refractory disease; revumenib has received initial regulatory approvals in select indications.
Biomarkers & Precision Medicine
Comprehensive molecular profiling at diagnosis and at relapse is now standard in AML. Findings shape risk classification, regimen choice, transplant decisions, and clinical trial eligibility. Biomarker-driven treatment is no longer optional in modern AML care.
When to Seek a Second Opinion
Decisions on the management of AML can be urgent and crucial. A specialist's advice would make an impact in many common situations. It is best to ask for another opinion prior to making critical decisions.
Clinical Trials & Research
Prognosis & Outcome Factors
AML outcomes vary widely by molecular and cytogenetic subtype, age, fitness, and access to specialist care including allogeneic transplant. The treatment landscape continues to evolve, and outcomes in several subtypes have improved substantially over the last decade. Pediatric AML generally has better outcomes than adult AML, though high-risk subtypes remain challenging across age groups.
Supportive Care & Living With AML
AML treatment is intensive and supportive care is central to outcomes. Infection prevention, transfusion support, nutritional care, and psychosocial support are part of comprehensive management throughout induction, consolidation, transplant, and survivorship.
How CancerFax Helps You Explore Treatment Options
For patients with AML, CancerFax provides structured review of bone marrow, cytogenetic, and molecular reports; second-opinion coordination with experienced hematology specialists; and guidance on access to FLT3/IDH inhibitors, venetoclax-based regimens, allogeneic transplant centers, CAR-T trials, and bispecific antibody trials โ including options at specialist centers in China and globally.
Get a free case reviewFrequently Asked Questions
AML is an aggressive cancer of the bone marrow that develops when myeloid precursor cells undergo malignant transformation and rapidly multiply, crowding out normal blood cell production. It can develop de novo, from a prior MDS, or after prior chemotherapy or radiation.
Diagnosis requires a bone marrow biopsy, immunophenotyping by flow cytometry, cytogenetics, and a molecular NGS panel covering FLT3, NPM1, IDH1/2, TP53, RUNX1, CEBPA, and other actionable mutations. Initial CBC, peripheral smear, and coagulation studies guide urgent workup, particularly to identify APL.
AML is classified by recurrent genetic abnormalities, by underlying pathology (de novo, MDS-related, therapy-related), and by morphology. Key molecular subtypes include APL (t(15;17)), core-binding factor AML, NPM1-mutated, FLT3-mutated, CEBPA-biallelic, KMT2A-rearranged, IDH-mutated, and TP53-mutated AML.
Yes. APL โ t(15;17) PML-RARA โ is treated with all-trans retinoic acid (ATRA) plus arsenic trioxide rather than standard chemotherapy. APL also carries a higher risk of disseminated intravascular coagulation at presentation, making it a hematologic emergency requiring prompt initiation of ATRA and aggressive blood product support.
For fit adults, induction is typically the '7+3' regimen (cytarabine + anthracycline) โ with midostaurin added for FLT3-mutated AML. CPX-351 is preferred for AML with myelodysplasia-related changes or therapy-related AML in selected patients. For older or unfit patients, hypomethylating agent plus venetoclax has become a widely used standard. Consolidation may include high-dose cytarabine, oral azacitidine maintenance, or allogeneic stem cell transplant depending on risk category and fitness.
Yes. Cytogenetics and NGS findings directly determine ELN risk category, eligibility for FLT3 and IDH inhibitors, choice of induction regimen, and whether allogeneic transplant should be planned in first remission. Modern AML management is not possible without these results.
Allogeneic transplant in first remission is generally recommended for adverse-risk AML and many intermediate-risk patients where a suitable donor is available and the patient is fit enough. Donor sources include matched related, matched unrelated, haploidentical, and umbilical cord. Conditioning intensity is selected based on age, fitness, and disease status.
Options for relapsed/refractory AML include gilteritinib (FLT3-mutated), ivosidenib or enasidenib (IDH-mutated), venetoclax-based combinations, salvage chemotherapy regimens, allogeneic transplant where feasible, menin inhibitors for KMT2A-rearranged or NPM1-mutated disease, and clinical trial enrollment in CAR-T, CAR-NK, and bispecific antibody studies.
A second opinion is particularly valuable at diagnosis (especially with adverse-risk biology), before deciding on allogeneic transplant in first remission, in relapsed or refractory disease, in molecular subgroups with targeted options (FLT3, IDH, KMT2A, NPM1), with unclear or conflicting molecular findings, and when considering clinical trial enrollment.
Yes. CancerFax supports AML patients with structured review of bone marrow, cytogenetic, and molecular reports; second-opinion coordination with experienced hematology specialists; biomarker interpretation; and access to FLT3/IDH inhibitors, venetoclax-based regimens, allogeneic transplant centers, CAR-T and bispecific antibody trials โ including options at specialist centers in China and globally.